672 Randomised phase II trial (M77001) of trastuzumab (Herceptin?) plus docetaxel versus docetaxel alone, as first-line therapy in patients with HER2-positive metastitic breast cancer

J.-M.Extra; F.Cognetti; S.Chan; D.Maraninchi; R.Snyder; a.Lluch; M.Tubiana-Hulin; D.Grimes; K.Mayne; M.Marty

首页> 外文期刊>European Journal of Cancer Supplements >672 Randomised phase II trial (M77001) of trastuzumab (Herceptin?) plus docetaxel versus docetaxel alone, as first-line therapy in patients with HER2-positive metastitic breast cancer

【24h】

672 Randomised phase II trial (M77001) of trastuzumab (Herceptin?) plus docetaxel versus docetaxel alone, as first-line therapy in patients with HER2-positive metastitic breast cancer

机译：672曲妥珠单抗（Herceptin？）加多西他赛与单独多西他赛的II期随机试验（M77001）作为HER2阳性转移性乳腺癌患者的一线治疗

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2003年第5期|共1页
作者
J.-M.Extra; F.Cognetti; S.Chan; D.Maraninchi; R.Snyder; a.Lluch; M.Tubiana-Hulin; D.Grimes; K.Mayne; M.Marty;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. 672 Randomised phase II trial (M77001) of trastuzumab (Herceptin?) plus docetaxel versus docetaxel alone, as first-line therapy in patients with HER2-positive metastitic breast cancer [J] . J.-M.Extra, F.Cognetti, S.Chan, European Journal of Cancer Supplements . 2003,第5期

机译：672曲妥珠单抗（Herceptin？）加多西他赛与单独多西他赛的II期随机试验（M77001）作为HER2阳性转移性乳腺癌患者的一线治疗
2. Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group. [J] . Inoue K, Nakagami K, Mizutani Breast cancer research and treatment. . 2010,第1期

机译：曲妥珠单抗单药治疗，曲妥珠单抗加多西他赛与曲妥珠单抗加多西他赛作为HER2阳性转移性乳腺癌患者的一线治疗的随机III期试验：JO17360试验组。
3. Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group [J] . Kenichi Inoue, Kazuhiko Nakagami, Mitsuhiro Mizutani, Breast Cancer Research and Treatment . 2010,第1期

机译：曲妥珠单抗单药治疗，曲妥珠单抗加多西他赛与曲妥珠单抗加多西他赛作为HER2阳性转移性乳腺癌患者的一线治疗的随机III期试验：JO17360试验组
4. Pemetrexed versus docetaxel single agent chemotherapy in chemotherapy-naive elderly patients with advanced non-small cell lung cancer [C] . Hua Xin, Zhenguo Han, Haibo Huang 2011 International Conference on Human Health and Biomedical Engineering . 2011

机译：培美曲塞与多西他赛单药化疗在未接受化疗的老年晚期非小细胞肺癌患者中的作用
5. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
6. Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer [O] . Edith A Perez, Sara A Hurvitz, Lukas C Amler, 2014

机译：TDM4450g中一线曲妥珠单抗艾坦相比曲妥珠单抗加多西他赛的疗效与HER2表达之间的关系：一项先前未经治疗的HER2阳性转移性乳腺癌患者的II期随机研究
7. Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5 [O] . John W. Smith, Marc E. Buyse, Priya Rastogi, 2017

机译：环磷酰胺蛋白与环磷酰胺，其次是多西紫杉醇与Trastuzumab和Bevacizumab为Neoadjuvant治疗，用于Her2阳性局部晚期乳腺癌，或作为HER2阳性病理阶段III乳腺癌的辅助治疗：NSABP基金会研究组的II期试验，FB-5

672 Randomised phase II trial (M77001) of trastuzumab (Herceptin?) plus docetaxel versus docetaxel alone, as first-line therapy in patients with HER2-positive metastitic breast cancer

著录项

相似文献

相关主题

期刊订阅